Foundayo / orforglipron
ApprovedThe release describes an oral small-molecule GLP-1 medicine approved in the US for weight management in adults with obesity, or overweight with a weight-related condition.
Develops medicines for diabetes, obesity, neuroscience, immune disorders and cancer, and is expanding US API manufacturing.
The release describes an oral small-molecule GLP-1 medicine approved in the US for weight management in adults with obesity, or overweight with a weight-related condition.
Broke ground on a USD 6.5 billion Houston API site. Production including Foundayo and over 600 jobs are plans, not evidence of completed operations.
Official role guide
Observed 2026-10-04
Information from a role guide does not establish a current vacancy.
Individual vacancy
Observed 2026-10-04
A brief based on selected official material, not an exhaustive product or vacancy list.